EUVIMEDEUVIMED entdecken
Crossref

Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma

Huong L Truong iD, Jason N Barreto iD, Kristin C Mara iD, Paul J Hampel iD, Ivana N Micallef iD, Grzegorz S Nowakowski iD, Gita Thanarajasingam iD, Carrie A Thompson iD, Yucai Wang iD, Thomas E Witzig iD, Sandra M Herrmann iD, Nelson Leung iD

JCO Oncology Practice · 2024

DOI: 10.1200/op.23.00628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Huong L Truong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Methotrexate, gamma-Glutamyl Hydrolase, Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Limited evidence exists regarding methotrexate (MTX) resumption after patients with lymphoma receive glucarpidase for toxic MTX levels and acute kidney injury (AKI). METHODS This retrospective review included adults with lymphoma treated with glucarpidase after MTX at Mayo Clinic between January 31, 2020, and October 10, 2022. Descriptive statistics summarize patient characteristics and clinical outcomes. RESULTS Of 11 patients treated with glucarpidase after MTX, seven (64%) were rechallenged with MTX. Indications for MTX rechallenge included confirmed CNS disease (n = 6, 86%) and intravascular lymphoma (n = 1, 14%). Compared with the nonrechallenged subgroup, before receiving MTX that required glucarpidase rescue, the rechallenged patients had lower median pretreatment serum creatinine (Scr; 0.7 v 1.2 mg/dL), and none had AKI with previous MTX doses, n = 0 (0%) versus n = 2 (50%). During the MTX dose requiring glucarpidase rescue, the rechallenged group had lower median peak Scr (1.26 v 3.32 mg/dL) and lower incidence of AKI stage III (n = 1 [14%] v n = 3 [75%]), and none of the rechallenged patients required renal replacement therapy (RRT; n = 0 [0%] v n = 1 [25%]). At the first rechallenge after glucarpidase administration, the median MTX dose reduction was 56% (range, 46%-75%), and the lowest used dose when prescribed according to each treatment protocol schedule was 1.5 g/m 2 . Two (29%) patients experienced AKI (n = 1 stage I, n = 1 stage II) after MTX rechallenge. Zero patients required RRT, and zero required another glucarpidase administration. Six (86%) patients completed all recommended MTX doses. CONCLUSION In selected adults with lymphoma who required glucarpidase for toxic MTX levels after administration of high-dose MTX, resumption of MTX therapy at lower doses is safe. Patients selected for MTX resumption had experienced less severe AKI during the previous cycle compared with those not selected for MTX resumption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methotrexategamma-Glutamyl HydrolaseLymphomaHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultAcute Kidney InjuryAntimetabolites, AntineoplasticRecombinant Proteins

Substanzen

Methotrexategamma-Glutamyl HydrolaseglucarpidaseAntimetabolites, AntineoplasticRecombinant Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Rochester, MN.
  • Loxo@Lilly, Lilly Corporate Center, Indianapolis, IN.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
  • Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Division of Nephrology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

ORCID-Profile: Huong L Truong, Jason N Barreto, Kristin C Mara, Paul J Hampel, Ivana N Micallef, Grzegorz S Nowakowski, Gita Thanarajasingam, Carrie A Thompson, Yucai Wang, Thomas E Witzig, Sandra M Herrmann, Nelson Leung

Zitieren

APA

Truong, H. L., Barreto, J. N., Mara, K. C., Hampel, P. J., Micallef, I. N., Nowakowski, G. S., Thanarajasingam, G., Thompson, C. A., Wang, Y., Witzig, T. E., Herrmann, S. M., & Leung, N. (2024). Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO Oncology Practice. https://doi.org/10.1200/op.23.00628

Vancouver

Truong HL, Barreto JN, Mara KC, Hampel PJ, Micallef IN, Nowakowski GS, et al. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO Oncology Practice. 2024. doi:10.1200/op.23.00628

BibTeX
@article{Truong2024,
  author = {Truong, Huong L and Barreto, Jason N and Mara, Kristin C and Hampel, Paul J and Micallef, Ivana N and Nowakowski, Grzegorz S and Thanarajasingam, Gita and Thompson, Carrie A and Wang, Yucai and Witzig, Thomas E and Herrmann, Sandra M and Leung, Nelson},
  title = {Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma},
  journal = {JCO Oncology Practice},
  year = {2024},
  doi = {10.1200/op.23.00628}
}
Kostenlos starten →